Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Roxindole"'
Autor:
K. Wiedemann, M. Kellner
Publikováno v:
Experimental and Clinical Endocrinology & Diabetes. 102:284-288
Roxindole (5-Hydroxy-3-(4-phenyl-1,2,3,6-tetrahydropyridil-(1)-butyl)-indol) is a newly developed compound with a high dopamine autoreceptor agonistic potency at D2 receptors. Evaluation of roxindole for clinical purposes in psychiatric patients reve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62ec6433b5371930e7aee81323953755
https://doi.org/10.1055/s-0029-1211293
https://doi.org/10.1055/s-0029-1211293
Autor:
Adrian Newman-Tancredi, Valérie Audinot, Lisa Maiofiss, Millan Mark, Didier Cussac, Jean-A. Boutin
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 303:791-804
Because little comparative information is available concerning receptor profiles of antiparkinson drugs, affinities of 14 agents were determined at diverse receptors implicated in the etiology and/or treatment of Parkinson's disease: human (h)D(1), h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af84a79b1572e45ec179150c3e9ff327
https://doi.org/10.1124/jpet.102.039867
https://doi.org/10.1124/jpet.102.039867
Publikováno v:
Naunyn-Schmiedeberg's Archives of Pharmacology. 359:447-453
Roxindole is a potential antidepressant agent. The present study determined its affinity and agonist efficacy at recombinant human (h) dopamine hD2, hD3 and hD4 and serotonin (5-HT) h5-HT1A, h5-HT1B and h5-HT1D receptors. Roxindole exhibited high aff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7ee3ec5c0874e16ad1b5be91dddf4b1
https://doi.org/10.1007/pl00005374
https://doi.org/10.1007/pl00005374
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Gerd Bartoszyk
Publikováno v:
Life Sciences. 62:649-663
The anxiolytic-like properties of dopamine agonists and antagonists with different receptor profiles were investigated in the ultrasonic vocalization test in rats after subcutaneous administration. Only dopamine D2 receptor agonists inhibited ultraso
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6c24ce949e829d7fa441ed4a438c09c
https://doi.org/10.1016/s0024-3205(97)01160-0
https://doi.org/10.1016/s0024-3205(97)01160-0
Autor:
Paul Willner
Publikováno v:
International Clinical Psychopharmacology. 12:S7-S14
Chronic treatment with antidepressant drugs produces a variety of changes in dopaminergic neurotransmission, most notably a sensitization of behavioural responses to agonists acting at dopamine D2/D3 receptors within the nucleus accumbens. Evidence f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92d152c21ea3974dc6c97a71ad154841
https://doi.org/10.1097/00004850-199707003-00002
https://doi.org/10.1097/00004850-199707003-00002
Publikováno v:
Psychopharmacology. 117:472-478
Roxindole is a potent autoreceptor-selective dopamine agonist with additional properties as a serotonin reuptake inhibitor and 5-HT1A agonist. In order to get more insight into its mode of action in various psychiatric populations, we evaluated the e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a051c672e50cd0936c4fd84e463572d
https://doi.org/10.1007/bf02246221
https://doi.org/10.1007/bf02246221
Publikováno v:
American Journal of Psychiatry. 151:1499-1502
Twenty schizophrenic inpatients with either predominantly positive or predominantly negative symptoms were treated with the dopamine autoreceptor agonist roxindole in prospective open clinical trials. There was no antipsychotic effect in the subgroup
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::459e208b1ca1e10c6d02734a191a6f9d
https://doi.org/10.1176/ajp.151.10.1499
https://doi.org/10.1176/ajp.151.10.1499
Publikováno v:
Psychopharmacology. 111:123-126
Roxindole is a potent autoreceptor-“selective” dopamine agonist originally developed for the treatment of schizophrenic syndromes. The drug also inhibits 5-HT uptake and has 5-HT1A agonistic actions. In this open clinical trial 12 in-patients suf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::365c54f15b672dab2842a0945ba2164c
https://doi.org/10.1007/bf02257418
https://doi.org/10.1007/bf02257418